Trastuzumab deruxtecan (T-DXd) sensitivity in various levels of HER2 expressing gastric cancer cells.

被引：0
|
作者：
Yu, Seo Young [1 ]
Park, Juin [2 ]
Kwon, Woo Sun [2 ]
Jeong, Inhye [2 ]
Kang, Sun Kyoung [2 ]
Bae, Hyun Joo [1 ]
Kim, Tae Soo [2 ]
Chung, Hyun Cheol [3 ]
Rha, Sun Young [3 ]
机构：
[1] Yonsei Univ, Coll Med, Brain Korea 21 PLUS Project Med Sci, Seoul, South Korea
[2] Yonsei Univ, Songdang Inst Canc Res, Coll Med, Seoul, South Korea
[3] Yonsei Univ Hlth Syst, Div Med Oncol, Dept Internal Med, Yonsei Canc Ctr, Seoul, South Korea
来源：
CANCER RESEARCH | 2021年 / 81卷 / 13期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
945
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Real-life experience of trastuzumab deruxtecan (T-DXd) in patients with heavily pretreated HER2 positive advanced breast cancer: A retrospective single institution study
    Vosoughi, Elham
    Nafissi, Nellie
    Mahadevan, Aditya
    Lee, Seungshin
    Parajuli, Kritisha
    Rijal, Nejina
    Parajuli, Ritesh
    Mehta, Rita S.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [22] Trastuzumab deruxtecan (T-DXd) in patients with human epidermal growth factor receptor 2 (HER2)-expressing salivary duct carcinoma: Subgroup analysis of two phase 1 studies.
    Bando, Hideaki
    Kinoshita, Ichiro
    Modi, Shanu
    Tsurutani, Junji
    Bang, Yung-Jue
    Iwata, Hiroji
    Sato, Yuta
    Nakatani, Shunsuke
    Lee, Caleb C.
    Sugihara, Masahiro
    Okuda, Yasuyuki
    Takahashi, Shunji
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [23] A PHASE 1/2 STUDY OF SBT6050 COMBINED WITH TRASTUZUMAB DERUXTECAN (T-DXD) OR TRASTUZUMAB AND TUCATINIB WITH OR WITHOUT CAPECITABINE IN PATIENTS WITH HER2-EXPRESSING OR HER2-AMPLIFIED CANCERS
    Klempner, Samuel
    Strickler, John
    Gourley, Lindsey
    Jacquemont, Celine
    Bhatia, Vinona
    Hunder, Naomi
    Odegard, Valerie
    Piha-Paul, Sarina
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A426 - A426
  • [24] Valemetostat and trastuzumab deruxtecan (T-DXd) in previously treated advanced or metastatic human epidermal growth factor receptor 2 (HER2)-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma
    Shitara, K.
    Enzinger, P. C.
    Mohapatra, A. S.
    Janjigian, Y. Y.
    ANNALS OF ONCOLOGY, 2024, 35 : S200 - S200
  • [25] Artificial intelligence analysis of advanced breast cancer patients from a phase I trial of trastuzumab deruxtecan (T-DxD): HER2 and histopathology features as predictors of clinical benefit
    Modi, S.
    Glass, B.
    Prakash, A.
    Taylor-Weiner, A.
    Elliott, H.
    Wapinski, I.
    Sugihara, M.
    Saito, K.
    Kerner, J. Kaplan
    Phillips, R.
    Shibutani, T.
    Honda, K.
    Khosla, A.
    Beck, A. H.
    Cogswell, J.
    ANNALS OF ONCOLOGY, 2020, 31 : S355 - S356
  • [26] DESTINY-PanTumor02 study of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: Exploratory biomarker analyses of HER2 expression and gene amplification in tissue and plasma
    Makker, V.
    Lee, J-Y.
    Oh, D-Y.
    Oaknin, A.
    Puvvada, S. D.
    Cecchi, F.
    Mcewen, R.
    Michelini, F.
    Meric-Bernstam, F.
    ANNALS OF ONCOLOGY, 2023, 34 : S239 - S240
  • [27] Trastuzumab Deruxtecan: Changing the Destiny of HER2 Expressing Solid Tumors
    Indini, Alice
    Rijavec, Erika
    Grossi, Francesco
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (09)
  • [28] PERCEPTIONS, EXPERIENCES, AND BEHAVIORS OF PATIENTS AND THEIR CAREGIVERS WITH GASTRIC AND GASTROESOPHAGEAL CANCER TREATED WITH OR WITHOUT TRASTUZUMAB DERUXTECAN (T-DXD) IN THE UNITED STATES
    Ghazarian, A.
    Henderson, M.
    Yalamanchili, P.
    Drinkwater, C.
    Nordland, R.
    Arunachalam, M.
    DeCotiis, G.
    Salas, M.
    VALUE IN HEALTH, 2024, 27 (06) : S295 - S295
  • [29] Real world data on Trastuzumab Deruxtecan (T-DXd) induced Interstitial Lung disease (ILD) in HER2 positive metastatic breast cancer patients at the Kent Oncology Centre
    Mohammed, S.
    Moss, C.
    Harper-Wynne, C.
    CLINICAL ONCOLOGY, 2025, 38
  • [30] Valemetostat and trastuzumab deruxtecan (T-DXd) in previously treated advanced or metastatic human epidermal growth factor receptor 2 (HER2)-positive gastric cancer or gastro-esophageal junction (GEJ) adenocarcinoma.
    Shitara, Kohei
    Enzinger, Peter C.
    Mohapatra, Avani
    Janjigian, Yelena Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : TPS508 - TPS508
12345